Curis (CRIS) AI Stock Analysis

• Market Cap: $18.25M
• Dividend Yield: N/A
• Average Volume (3M): 68.01K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.73
• Revenue Growth: 13.56%
• EPS Growth: 52.92%
• Country: US
• Employees: 34
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.49
• Shares Outstanding: 12,498,853
• 10 Day Avg. Volume: 74,344
• 30 Day Avg. Volume: 68,010
• PEG Ratio: 0.02
• Price to Book (P/B): -3.22
• Price to Sales (P/S): 1.77
• P/FCF Ratio: -0.49
• Enterprise Value/Market Cap: 2.83
• Enterprise Value/Revenue: 4.43
• Enterprise Value/Gross Profit: 4.45
• Enterprise Value/Ebitda: -1.55
• 1Y Price Target: $11.00
• Price Target Upside: 816.67% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $1.00 ▼(-16.67% Downside)

Curis's overall stock score is primarily impacted by its weak financial performance and valuation metrics, reflecting ongoing financial instability and lack of profitability. While the earnings call provided some positive clinical updates, concerns about cash reserves and technical indicators pointing to a bearish trend further weigh down the score.

Positive Factors

Promising Clinical Progress

Curis's AML triplet study showed MRD conversion to undetectable levels in 4 of 8 patients, indicating effective treatment potential and strengthening its drug pipeline.

Strategic Focus on Key Drug Development

Curis is advancing emavusertib in combination with ibrutinib for CNS lymphoma, aiming for accelerated submissions, which could enhance its market position in oncology.

Reduced Financial Losses

Curis's reduced net loss demonstrates improved financial management and operational efficiency, potentially leading to better financial stability.

Negative Factors

Limited Cash Reserves

Curis's limited cash reserves may only fund operations into 2026, posing a risk to its ability to sustain long-term R&D and operational activities.

Negative Stockholders' Equity

Negative stockholders' equity indicates liabilities exceed assets, highlighting potential solvency issues and financial instability, which could impact future growth.

Dose-Limiting Toxicities in Studies

Dose-limiting toxicities in clinical trials could hinder drug development progress and regulatory approvals, affecting Curis's long-term product pipeline success.

Curis Business Overview & Revenue Model

Company Description

Curis, Inc. (CRIS) is a biotechnology company focused on the development of innovative drug therapies for the treatment of cancer. The company specializes in the discovery and development of targeted medicines, primarily focusing on small molecule drug candidates that modulate specific signaling pathways in cancer cells. Curis operates within the oncology sector, aiming to provide effective solutions for patients with various types of cancer through its proprietary drug development programs and collaborations with other pharmaceutical companies.

How the Company Makes Money

Curis generates revenue through a combination of product sales, licensing agreements, and collaborations. The primary revenue stream comes from the development and commercialization of its drug candidates, which may include upfront payments, milestone payments, and royalties from partnered products. The company also engages in strategic partnerships with larger pharmaceutical companies, which provide funding for research and development in exchange for rights to market or co-develop certain products. Additionally, Curis may receive government grants or funding for specific research initiatives, further contributing to its earnings.

Curis Financial Statement Overview

Summary

Curis faces significant financial challenges with persistent losses and negative cash flows. The balance sheet reveals negative stockholders' equity, indicating potential solvency issues. Despite some revenue growth, the company's profitability and balance sheet stability are concerning.

Income Statement

Curis shows a slight increase in revenue from the previous year, but the company still suffers from significant negative net income and EBIT margins, indicating ongoing profitability issues. The gross profit margin remains positive, but the net profit margin is deeply negative, reflecting operational challenges.

Balance Sheet

The balance sheet reveals a negative stockholders' equity, which is concerning, indicating that liabilities exceed assets. The debt-to-equity ratio is not calculable due to negative equity. This highlights potential solvency issues and financial instability.

Cash Flow

Curis has negative free cash flow and operating cash flow, which are troubling. The cash flow from operations is consistently negative, which may indicate difficulties in generating cash from core activities. Despite some improvement in cash flow from investing activities, the overall cash flow position remains weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	11.65M	10.91M	10.02M	10.16M	10.65M	10.84M
Gross Profit	11.59M	10.81M	9.81M	9.90M	10.12M	10.30M
EBITDA	-33.20M	-42.57M	-45.14M	-51.67M	-40.81M	-24.67M
Net Income	-36.56M	-43.39M	-47.41M	-56.67M	-45.44M	-29.91M
Balance Sheet
Total Assets	27.64M	41.27M	77.28M	108.85M	162.30M	204.36M
Cash, Cash Equivalents and Short-Term Investments	9.05M	20.00M	56.33M	85.62M	115.88M	168.49M
Total Debt	30.60M	2.95M	2.79M	3.94M	5.04M	7.66M
Total Liabilities	42.33M	47.26M	57.61M	62.30M	71.59M	73.69M
Stockholders Equity	-14.69M	-6.00M	19.67M	46.55M	90.71M	130.67M
Cash Flow
Free Cash Flow	-30.09M	-39.56M	-38.43M	-54.75M	-37.62M	-26.42M
Operating Cash Flow	-30.09M	-39.56M	-38.43M	-54.34M	-37.62M	-25.74M
Investing Cash Flow	-428.00K	29.44M	37.79M	33.02M	-47.90M	-49.05M
Financing Cash Flow	18.71M	3.44M	7.58M	867.00K	-4.17M	188.81M

Curis Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.20
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRIS, the sentiment is Negative. The current price of 1.2 is below the 20-day moving average (MA) of 1.24, below the 50-day MA of 1.44, and below the 200-day MA of 1.89, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 46.66 is Neutral, neither overbought nor oversold. The STOCH value of 54.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRIS.

Curis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PULM	53 Neutral	$16.40M	―	-79.47%	―	-99.97%	35.59%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MBRX	44 Neutral	$24.59M	-0.11	―	―	―	79.31%
CRIS	44 Neutral	$18.25M	-0.30	―	―	13.56%	52.92%
BGMS	38 Underperform	$3.56M	>-0.01	-226.28%	10.34%	9.46%	96.85%
RLYB	35 Underperform	$26.30M	-0.68	-21.17%	―	12.71%	79.93%
ELEV	33 Underperform	―	―	―	―	―	47.73%

Curis Corporate Events

Curis Inc. Earnings Call: Clinical Progress and Financial Gains

Curis Inc. recently held its earnings call, revealing a generally positive sentiment driven by significant progress in clinical studies and improved financial performance. Despite concerns about limited cash reserves and some dose-limiting toxicities in their AML triplet study, the promising clinical results and reduced financial losses compared to the previous year were highlighted as key positive aspects.

Curis Inc. Advances Cancer Trials with Promising Results

Curis Inc., a biotechnology firm, is advancing its clinical studies with a focus on emavusertib, a small molecule inhibitor targeting IRAK4 and FLT3, primarily in the treatment of various cancers. In its third-quarter 2025 report, Curis highlighted significant progress in its clinical trials, particularly in Primary CNS Lymphoma (PCNSL), Chronic Lymphocytic Leukemia (CLL), and Acute Myeloid Leukemia (AML). The company is preparing for several key presentations at upcoming medical conferences, showcasing promising data from these studies.

Curis Completes Sale of Erivedge Business

On November 6, 2025, Curis completed the sale of its Erivedge Business to TPC Investments Royalty LLC, managed by Oberland, for $2.5 million and a release of liability related to future royalties. This transaction will result in a gain for Curis in the fourth quarter of 2025 and extinguish its royalty-related liabilities, although it will no longer receive revenues under the License Agreement. Additionally, Curis is actively pursuing compliance with Nasdaq listing requirements after receiving an exception period until November 14, 2025, to meet the market value listing standard. The company is also advancing its clinical studies in PCNSL, CLL, and AML, with significant progress in enrolling patients and presenting data at upcoming conferences, which could potentially enhance its market positioning and stakeholder confidence.

The most recent analyst rating on (CRIS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Curis stock, see the CRIS Stock Forecast page.

Curis Inc.’s Promising Study on Emavusertib for AML and MDS: A Potential Game-Changer

Curis Inc. is conducting a clinical study titled A Phase 1/2A, Open Label Dose Escalation and Expansion Study of Orally Administered CA-4948 as a Monotherapy in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome. The study aims to evaluate the safety and efficacy of emavusertib (CA-4948), a novel IRAK4 inhibitor, in treating patients with relapsed or refractory acute myelogenous leukemia (AML) or higher-risk myelodysplastic syndrome (MDS). This research is significant as it targets genetic mutations often found in these conditions, potentially offering new treatment options.

Curis Inc. Advances Lymphoma Treatment with Emavusertib Study

Curis Inc. is conducting an open-label study titled ‘CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL).’ The study aims to evaluate the safety, pharmacokinetics, and anti-cancer activity of emavusertib, alone or in combination with ibrutinib, in patients with relapsed or refractory hematologic malignancies. This research is significant as it explores potential new treatments for challenging lymphoma cases.

Curis Granted Nasdaq Compliance Extension Until November

Curis, Inc. is facing a potential delisting from the Nasdaq Capital Market due to non-compliance with the market value of listed securities requirement, which mandates a minimum of $35 million. After receiving a delisting notice on August 21, 2025, Curis requested a hearing, which temporarily halted the delisting process. On October 20, 2025, Nasdaq granted Curis an exception until November 14, 2025, to regain compliance. The company must notify Nasdaq of any significant developments during this period, but there is no guarantee of maintaining its listing.

The most recent analyst rating on (CRIS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Curis stock, see the CRIS Stock Forecast page.

Curis Appeals Nasdaq Delisting Notice After Non-Compliance

On February 21, 2025, Curis, Inc. was notified by Nasdaq that it was not in compliance with the market value listing standard, as its securities’ market value had been below $35 million for 30 consecutive trading days. Despite a 180-day compliance period ending on August 20, 2025, Curis failed to meet the requirement and was informed on August 21, 2025, that its securities would be delisted unless it appealed the decision. Curis intends to request a hearing to appeal, which will temporarily halt the delisting process, but there is no guarantee of regaining compliance.

The most recent analyst rating on (CRIS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Curis stock, see the CRIS Stock Forecast page.